Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Apr 7, 2015 at 10:45 AM EDT

Dyax Shares Defy Gravity on Secondary Offering News

The newest hot stock in biotechnology is now giving everyone the chance to get a piece of it via an…

Lee Jackson | Apr 7, 2015 at 10:30 AM EDT

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product…

Chris Lange | Apr 6, 2015 at 12:45 PM EDT

Is a Big Share Buyback Coming to DaVita?

DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend.…

Lee Jackson | Apr 6, 2015 at 9:20 AM EDT

Catalysts and Data Could Move 4 Top Biotech Stocks to Buy

A new report from Stifel highlights four very solid biotech stocks that could bring home the bacon this year for…

Jon C. Ogg | Apr 4, 2015 at 9:25 AM EDT

4 Fresh Biotech Stock Picks With Targets 50% to 100% Higher

In the past week there were four analyst picks in and associated with the biotech area that came with gigantic…

Chris Lange | Apr 3, 2015 at 8:50 AM EDT

Is Nymox a Fluke or Is It Back?

Nymox Pharmaceutical shares rallied over 100% in the past week. Was that a fluke, or is Nymox really back in…

Chris Lange | Apr 1, 2015 at 12:10 PM EDT

Does the Mylan Secondary Make Its Stock Cheap?

Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the…

Chris Lange | Apr 1, 2015 at 11:20 AM EDT

Biotechs Raising New Capital in Droves

With the biotech industry so hot, it seems like many of the smaller players are trying to bolster their balance…

Chris Lange | Apr 1, 2015 at 10:15 AM EDT

Analysts Massively Increasing Dyax Price Targets

So far, analysts have not backed off their bullish views of Dyax. In fact, many analysts boosted their price targets…

Chris Lange | Mar 31, 2015 at 5:11 PM EDT

Why Dyax Will Dominate Biotech News on Wednesday

Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday…

Chris Lange | Mar 31, 2015 at 3:45 PM EDT

Ebola Finances Coming Back in the News

Within the past week, two Ebola-related companies are showing renewed optimism for their positions, whether it is securing a contract…

Chris Lange | Mar 30, 2015 at 1:50 PM EDT

Are Auspex Shareholders Getting Enough in the Buyout?

News broke Monday that Teva Pharmaceutical Industries will acquire Auspex Pharmaceuticals. Existing investors will be wondering if they are getting…

Chris Lange | Mar 30, 2015 at 12:25 PM EDT

Can Boston Scientific Keep Its Turnaround Gains Going?

Boston Scientific shares are up almost 50% in the past six months, and the stock has more than doubled from…

Jon C. Ogg | Mar 30, 2015 at 10:25 AM EDT

Why a PBM Acquisition Is Taking UnitedHealth to All-Time Highs

Catamaran, a provider of pharmacy benefit management services and technology solutions, announced Monday morning that it has agreed to merge…

Lee Jackson | Mar 27, 2015 at 8:35 AM EDT

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they…

1 … 266 267 268 269 270 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Dyax Shares Defy Gravity on Secondary Offering News

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

Is a Big Share Buyback Coming to DaVita?

Catalysts and Data Could Move 4 Top Biotech Stocks to Buy

4 Fresh Biotech Stock Picks With Targets 50% to 100% Higher

Is Nymox a Fluke or Is It Back?

Does the Mylan Secondary Make Its Stock Cheap?

Biotechs Raising New Capital in Droves

Analysts Massively Increasing Dyax Price Targets

Why Dyax Will Dominate Biotech News on Wednesday

Ebola Finances Coming Back in the News

Are Auspex Shareholders Getting Enough in the Buyout?

Can Boston Scientific Keep Its Turnaround Gains Going?

Why a PBM Acquisition Is Taking UnitedHealth to All-Time Highs

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Three Value Focused ETFs Pay Solid Dividends and Keep Outperforming the Market in 2026

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Health and Healthcare Articles

All Health and Healthcare Articles

Dyax Shares Defy Gravity on Secondary Offering News

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

Is a Big Share Buyback Coming to DaVita?

Catalysts and Data Could Move 4 Top Biotech Stocks to Buy

4 Fresh Biotech Stock Picks With Targets 50% to 100% Higher

Is Nymox a Fluke or Is It Back?

Does the Mylan Secondary Make Its Stock Cheap?

Biotechs Raising New Capital in Droves

Analysts Massively Increasing Dyax Price Targets

Why Dyax Will Dominate Biotech News on Wednesday

Ebola Finances Coming Back in the News

Are Auspex Shareholders Getting Enough in the Buyout?

Can Boston Scientific Keep Its Turnaround Gains Going?

Why a PBM Acquisition Is Taking UnitedHealth to All-Time Highs

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

These 3 S&P 500 ETFs Are Nearly Identical But After Doing the Math One of Them Saves You Money Over a Lifetime

Three Value Focused ETFs Pay Solid Dividends and Keep Outperforming the Market in 2026

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later